Physician profile
Behdad Akbarpour
NPI 1760604979
$32,534.58
in general payments reported to CMS, 2019-2025
49 companies · $5,541 in 2025
The $5,541 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,058 · 2020: $2,395 · 2021: $3,481 · 2022: $5,928 · 2023: $6,164 · 2024: $4,968 · 2025: $5,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,673.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,354.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Nestle Healthcare Nutrition INC. | $2,932.92 | 2020-2023 | |
| Novo Nordisk INC | $2,782.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,901.12 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,833.85 | 2019-2025 | Jardiance |
| Amgen INC. | $1,790.11 | 2020-2025 | Otezla, Repatha, Otezla |
| Aimmune Therapeutics, INC. | $1,749.05 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $1,569.43 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $1,349.76 | 2019-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $1,282.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,272.06 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $1,184.23 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $1,112.37 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $605.24 | 2024-2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $551.85 | 2023-2025 | Horizant, Horizant, Edarbi |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behdad Akbarpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.